New Therapeutic Options for BRCA Mutant Patients

Abstract excerpt

Pathogenic variants in BRCA1 and BRCA2 are associated with significantly elevated lifetime risks of breast, ovarian, pancreatic, and prostate cancer. These genes are critical in double-strand break repair through homologous recombination. An understanding of the biology of BRCA1 and BRCA2 led to the development of targeted therapeutics, specifically poly(ADP-ribose) polymerase (PARP) inhibitors, which are...

Topics

Join the communities discussing this publication.

• BRCA gene mutations in cancer
• CRISPR and Genetic Engineering
• PARP inhibition in cancer therapy